Neovasc Inc. Reports Second Quarter 2009 Financi...(Interest on repayable co...),Health

Date:8/19/2009

Interest on repayable contribution agreement - 3,846 - 7,685 Stock-based compensation 40,399 16,457 126,451 29,740 ------------------------------------------------------------------------- (1,258,949) (1,725,296) (2,886,781) (3,403,983) Change in non-cash operating assets and liabilities Accounts receivable (106,089) 38,235 28,417 228,316 Inventory (35,974) 81,126 (184,586) (88,034) Prepaid expenses and other assets 115 (40,440) (6,164) (169,585) Accounts payable and accrued liabilities (192,967) 118,393 (59,232) 105,493 ------------------------------------------------------------------------- (1,593,864) (1,527,982) (3,108,346) (3,327,793) ------------------------------------------------------------------------- INVESTING ACTIVITY Purchase of property and equipment (574) (6,510) (8,545) (13,692) ------------------------------------------------------------------------- (574) (6,510) (8,545) (13,692) ------------------------------------------------------------------------- FINANCING ACTIVITIES Repayment of long-term debt (17,287) (7,265) (22,318) (12,035) Repayment of repayable contribution agreement - (2,655) - (4,383) Proceeds from share issue, net of costs 1,979,686 - 1,979,686 - Proceeds from exercise of stock options - - 1,555 -
'/>"/>

SOURCE Neovasc Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites